LIST OF FIGURES

Figur	e	Title		Af	ter Page
2-1	Calibration curve in dissolution med	~	ne hydrochlor	ide	47
2 - 2	Calibration curve in human urine	of tetracycli	ne hydrochlor	ide	47
2 - 3	Calibration curve in dissolution med	•	e hydrochlori	de •••	53
2-4	Calibration curve in dog plasma	of hydralazin	e hydrochlori	de •••	53
3-1	Cumulative percent hydrochloride from capsules	_	-	.e	86
3 - 2	Cumulative percent hydrochloride from P.V.P. matrix caps	cellulose ac	-		87
3 - 3	Cumulative percent hydrochloride from coated beads	_	-	.e	91
3 - 4	Cumulative percent hydrochloride from coated beads	_		.e	92
3- 5	Cumulative percent hydrochloride from phthalate coated k	cellulose ac	•	.e	93
3– 6	Cumulative percent hydrochloride from	_	~		94
3 - 7	Cumulative percent	_			95

Figur	e Title ,	After	Page
3 - 8	Cumulative percentage release of tetracycline hydrochloride from eudragit RL100 coated beads 1.	96	;
3- 9	Cumulative percentage release of tetracycline hydrochloride from eudragit RS100 coated beads	97	,
3-10	Cumulative percentage release of tetracycline hydrochloride from eudragit RL100/RS100 (50:50) coated beads	98	, }
3-11	Cumulative percentage release of tetracycline hydrochloride from eudragit RS100 coated beads*	99)
3 - 12	* Plain beads contain higher concentration of tetracycline hydrochloride (75%) Cumulative percentage release of tetracycline hydrochloride from eudragit RS100 coated beads* * 10% avicel was replaced with eudragit RSPM	100)
3-13	Cumulative percentage release of tetracycline hydrochloride from glyceryl monostearate matrix tablets	104	ŀ
3 - 14	Cumulative percentage release of tetracycline hydrochloride from glyceryl distearate matrix tablets	105	;
3- 15	Cumulative percentage release of tetracycline hydrochloride from eudragit RLPM matrix tablets.	106	
3- 16	Cumulative percentage release of tetracycline hydrochloride from eudragit RSPM matrix tablets	107	
3-17A	Cumulative percentage release of tetracycline hydrochloride from eudragit RSPM/RLPM matrix tablets (500 mg)	. 108	
3-17 B	Cumulative percentage release of tetracycline hydrochloride from eudragit RSPM/RLPM matrix		
	tablets (250 mg)	108	

Figure	9	Title		After	Page
3-18A	Photomicrograph of beads of tetracycli	-		•••	119_
3-1 8B	Photomicrograph of beads of tetracycli and coating (X 100)	ne hydrochlo		re •••	112
3 -1 9	Cumulative percenta hydrochloride from coated beads		•	• • •	122
3- 20	Cumulative percenta hydrochloride from beads	_	· ·	. • •	123
3 - 21	Cumulative percenta hydrochloride from	•	-	•••	124
3 - 22	Cumulative percenta hydrochloride from		-	5	125
3 - 23	Cumulative percenta hydrochloride from	—	-	••	126
3-24	Cumulative percenta hydrochloride from coated beads	_	_	• • •	127
	Cumulative percenta hydrochloride from matrix tablets	_	•	•••	130
3 - 26	Cumulative percenta, hydrochloride from tablets		· ·	•••	131
3 - 27	Cumulative percenta, hydrochloride from		-		132
3 - 28	Cumulative percenta, hydrochloride from		_		133

Figure	e ·	Title		After	Page
3 -2 9	Cumulative percentage r hydrochloride from eudr tablets	•		•••	134
3-30A	Photomicrograph of eudroff hydralazine hydrochl	_	ated beads	•••	136
3-3 0B	Photomicrograph of eudrof hydralazine hydrochl coating (X 100)	-		•••	136
4-1	Comparative urinary exc hydrochloride after ora controlled release and	l administrat:	ion of		144
4-2	Predicted serum levels administration of contr conventional products	-			145
-	Plasma levels of hydral tion of conventional an products.				153
	Stability studies of te	·	l roc h lori de		167
	Stability studies of te		irochloride		167
	Stability studies of te		lrochloride		167
	Stability studies of te controlled release tabl	•	lrochloride		167
	Stability studies of hy controlled release caps	· · · · · · · · · · · · · · · · · · ·	rochloride	•••	173
	Stability studies of hy controlled release tabl		ochloride	•••	173